Needham analyst Mayank Tandon downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Hold.
Boeing CEO Says Forecasts Do Not Require It To Resume Sales To China
- Reuters Citing Investor Day
Needham Downgrades Duck Creek Technologies to Hold
Needham analyst Mayank Tandon downgrades Duck Creek Technologies (NASDAQ:DCT) from Buy to Hold.
Related Posts
Inhibrx Initiates A Registration-Enabling Trial Of INBRX-101 In AATD And Announces Lift Of Partial Clinical Hold On INBRX-109 DR5 Agonist Trials
Inhibrx, Inc. (NASDAQ:INBX), a clinical-stage biopharmaceutical company dedicated to the development of therapeutics for oncology and rare diseases, announced today that it has initiated a registration-enabling
13 Analysts Have This to Say About Eaton Corp
Analysts have provided the following ratings for Eaton Corp (NYSE:ETN) within the last quarter: Bullish Somewhat Bullish Indifferent…
Palisade Bio Presents Development Overview Of PALI-2108 At The IBD Innovate: Product Development For Crohn’s & Colitis April 9-10, 2024 In Cambridge, MA
– PALI-2108 in development for the treatment of moderate-to-severe ulcerative colitis (UC) advancing towards Phase 1 clinical study before year endCarlsbad, CA, April 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio,